I graduated from Peking University with a B.Sc. degree in Pharmaceutical Sciences before moving to the Peking Union Medical College, Chinese Academy of Medical Sciences to carry on my PhD. My PhD project was focused on targeting drug delivery system construction for cancer therapy where I found a novel peptide for targeting non-small cell lung cancer. After my PhD, I joined the University of Birmingham as a research fellow and start working on a project to investigate new treatments for cancer by drug redeployment research to provide affordable therapies that can be exploited by all including the worlds poorer nations. Our finding suggested a triple-drug combination could form an effective and non-toxic treatment for a range of aggressive blood cancers. This study has led to a clinical trial in 2021 (NCT04997811).
I joined the University of Oxford in 2022 as a postdoctoral researcher on tumour biology working in Kerr/Cai group.
International Journal of Molecular Sciences
GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner.
Wang Z. et al, (2023), Cancer Res